Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Dopamine Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Dopamine Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Dopamine Agonists are drugs that act upon Dopamine receptors located in the body, specifically in the brain, and activate them by mimicking the action of natural dopamine. Dopamine plays a dual role in our body by acting as a neurotransmitter as well as a neurohormone. It plays a role in body movements, memory, and pleasurable rewards and motivation. It is secreted during pleasurable situations, and therefore, dopamine is known to influence a person’s mood and feelings. A disbalance of dopamine levels in the brain has been associated with many behavioral and mental disorders like Anxiety, Dementia, Parkinson’s disease (PD), and others. Conditions like Parkinson’s disease (PD) are characterized by low dopamine levels in the central nervous system. Hence, agonists are used to treat the symptoms of the disease and slow its progression. Research is being conducted globally to discover new and novel molecules to be used as dopamine agonists that may increase the level of dopamine in dopamine-deficient patients. The development and launch of new products will thus increase the market’s revenue in the forecasted years. According to the International Parkinson and Movement Disorder Society 2023 report, an estimated 9.4 million people globally are living with PD in 2020. According to the Parkinson’s Foundation 2023 report, nearly 1 million US residents have PD, while approximately 90,000 people are diagnosed yearly. The number of patients suffering from PD is expected to reach 1.2 million by 2030 in the USA. The prevalence of the disease has been rising continuously for many decades, which marks an opportunity for the market players.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. 48 companies have various products in their pipelines, with 55 products in various stages of clinical trials. 9 products in Phase 4, 10 in Phase 3, 13 in Phase 2, and 9 in Phase 1 of the clinical trials.
Key Developments of Dopamine Agonists
Approved molecules of Dopamine Agonists
Drugs in the Pipeline of Dopamine Agonists
Clinical Activity and Developments of Dopamine Agonists
As of June 2023, 48 companies have approximately 55 products for 285 diseases. For these diseases, 104 trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
Duodopa (levodopa/carbidopa intraduodenal gel infusion) |
38 |
|
Permax (pergolide) |
13 |
|
Cycloset (bromocriptine) |
12 |
|
Gocovri (amantadine ER) |
11 |
|
Xywav (calcium/magnesium/potassium/sodium oxybates) |
8 |
Drugs like Duodopa (levodopa/carbidopa intraduodenal gel infusion) and Permax (pergolide) Have been approved by the FDA and other regulatory agencies for the treatment of various indications. These are indicated for use alone or in combination with other therapies to derive maximum output. Duodopa is indicated for treating patients with advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and dyskinesia or hyperkinesia. Permax is indicated as an adjuvant treatment to levodopa/carbidopa for the management of signs and symptoms of Parkinson’s disease. Other indications are which Dopamine Agonists are used are Basal Ganglia disorders, Mood disorders, Dyskinesia, Psychotic disorders, Dementia, Dyssomnia, and many others.
Jazz Pharmaceuticals’ Xywav had global net sales of $958.4 million in the financial year 2022 while in 2021 was $535.29 million marking a 79% increase in net sales. Also, Xywav had net sales of $281.38 million in the 4th quarter of the financial year 2022 and $182.65 million in 2021, which was an increase of 54%. Supernus Pharmaceuticals’ Gocovri had global net sales of $104.4 million in the financial year 2022, which was a 79% increase from net sales of 2021. Gocovri’s 4th quarter 2022 net product sales were $29.2 million, which was 13% higher compared to the 4th quarter net sales in 2021. There has been a rising trend in the prevalence rates of the diseases indicated for Dopamine Agonists globally that is an opportunity for the market players to launch new and innovative products.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Duodopa (levodopa/carbidopa intraduodenal gel infusion), Permax (pergolide), Cycloset (bromocriptine), and Gocovri (amantadine ER) are some of the molecules approved by various regulatory agencies.
These are used to treat Parkinson’s disease, Mood disorders, Dyskinesia, Psychotic disorders, Dementia, Dyssomnia, and others.
Knopp Biosciences, Biogen, Acorda Therapeutics, Eli Lilly, and Bausch Health are some of the major market players for Dopamine agonists.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to various disorders like Parkinson’s disease (PD), Idiopathic Hypersomnia (IH) are the key opportunities for Dopamine agonists in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.